BioArctic publishes the Annual Report for 2018

Stockholm, Sweden, April 16, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2018 fiscal year has been ...

Full Year Report January – December 2018

BioArctic’s partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer’s disease. AbbVie in-licensed the Parkinson portfolio

Proud partner of: